28 Amendments of Françoise GROSSETÊTE related to 2010/2153(INI)
Amendment 7 #
Motion for a resolution
Recital A
Recital A
Amendment 12 #
Motion for a resolution
Recital A a (new)
Recital A a (new)
Aa. whereas, under the International Health Regulations (IHR) – a legal instrument binding on the states parties to it – the remit of the WHO includes public health surveillance, coordinating international public health measures and, in relation to potentially pandemic viruses, determining current phases of alert on a scale of one to six,
Amendment 13 #
Motion for a resolution
Recital A b (new)
Recital A b (new)
Ab. whereas the phases of a global pandemic are determined in accordance with the provisions of the IHR and in consultation with other organisations and institutions and with the Member States affected,
Amendment 14 #
Motion for a resolution
Recital B
Recital B
Amendment 22 #
Motion for a resolution
Recital B a (new)
Recital B a (new)
Ba. Considering the high degree of unforeseeability and severity of how the pandemic was going to unfold, always with the possibility that the pandemic might worsen in Europe, as it did in 1918 and 1968;
Amendment 28 #
Motion for a resolution
Recital C
Recital C
Amendment 40 #
Motion for a resolution
Recital E
Recital E
Amendment 56 #
Motion for a resolution
Recital G
Recital G
Amendment 60 #
Motion for a resolution
Recital I
Recital I
Amendment 69 #
Motion for a resolution
Recital J
Recital J
Amendment 72 #
Motion for a resolution
Recital J a (new)
Recital J a (new)
Ja. whereas the vaccines’ benefit-risk ratio has now been demonstrated in tolerance and immunogenicity studies based on actual use,
Amendment 74 #
Motion for a resolution
Subheading 1
Subheading 1
Amendment 80 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Emphasises the need to reinforce cooperation between Member States within the EU in the management of the response to a pandemic, within the framework of WHO, according to the International Health Regulation of 2005 ;
Amendment 81 #
Motion for a resolution
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Wants to reinforce the collaboration between Member States by ensuring coherent risk assessment and risk management for fast evolving threats at EU level by putting in place, where necessary, additional structures and coordination mechanisms;
Amendment 82 #
Motion for a resolution
Paragraph 1 c (new)
Paragraph 1 c (new)
1c. Is delighted about the fact that the Commission committed itself studying the possibility of a revision and, should this happen, a long-term reinforcement of the legal base of Health Security Committee;
Amendment 83 #
Motion for a resolution
Paragraph 1 d (new)
Paragraph 1 d (new)
1d. Requests to give a special attention to the preparation between sectors within the framework of the co-operation between Member States within the Health Security Committee;
Amendment 87 #
Motion for a resolution
Paragraph 1 h (new)
Paragraph 1 h (new)
1h. Urges the European Union to allot more means to the research and the development while conforming to the objective which it assigned to allocate 3% of the European GDP to the R & D; more specifically claim an increase in the investments dedicated to a better evaluation and anticipation of the impact of an influenza virus as well in period between pandemic as at the beginning of a pandemic;
Amendment 88 #
Motion for a resolution
Paragraph 1 i (new)
Paragraph 1 i (new)
1i. Welcomes the Commission's commitment to develop a mechanism for joint procurement of vaccines and antiviral medication which allows Member States, on a voluntary basis, a common acquisition of these products or common approaches to contract negotiations with the pharmaceutical industry; Recalls that only the seeking for joint solutions for a common purchasing of vaccines and antiviral medications will ensure equitable access, at the lowest price for the Member States;
Amendment 89 #
Motion for a resolution
Paragraph 1 j (new)
Paragraph 1 j (new)
1j. Calls for continued investment in national epidemiological, serological and virological surveillance centres;
Amendment 90 #
Motion for a resolution
Paragraph 2
Paragraph 2
Amendment 97 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Demands that robust, crediblePoints out the need for and effective scientific procedures be introduced for the evaluation of medicinal products recommended in the event of health emergencies, and more particularly in genuine pandemic, independent, transparent and balanced scientific report for the evaluation of the drugs including in health emergency situations;
Amendment 101 #
Motion for a resolution
Paragraph 4
Paragraph 4
Amendment 111 #
Motion for a resolution
Paragraph 5
Paragraph 5
Amendment 119 #
Motion for a resolution
Paragraph 5 c (new)
Paragraph 5 c (new)
5c. Requests the installation of a definition of the conflict of interest which is common to all the European agencies ;
Amendment 130 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Considers theat all conflicts of interest apparent in the case of some experts who advise the European institutions to give rise to suspicions of undue influence and to undermine the overall credibility of the European health agencies and their recommendations; calls in particular for the EMA and ECDC to revise forthwith their current and future expert screening procedures to ensure completemust be avoided; welcomes the new European Medical Agency (EMA) rules, which make for greater transparency;
Amendment 147 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Calls for full liability for the quality, safety and effectiveness of a medicinal product to rest with the manufacturer, as required by EU law;
Amendment 151 #
Motion for a resolution
Paragraph 10 b (new)
Paragraph 10 b (new)
10b. Requires a global European strategic approach for the so-called “at-risk” groups on how to reach them and communicate with them in case of pandemics;
Amendment 156 #
Motion for a resolution
Subheading 3 a (new)
Subheading 3 a (new)
Within the framework of the common and liable management of supply of vaccines, request to think over the possibility of easing the access of developing countries to vaccinal products in case of a pandemic;